Journal Articles

Donald and Barbara Zucker School of Medicine
Academic Works

2015

N-Acetylcysteine attenuates tumor necrosis factor
alpha levels in autoimmune inner ear disease
patients
S. Pathak
Hofstra Northwell School of Medicine

C. Stern
Northwell Researcher

A. Vambutas
Hofstra Northwell School of Medicine

Follow this and additional works at: https://academicworks.medicine.hofstra.edu/articles
Part of the Medical Molecular Biology Commons, and the Otolaryngology Commons
Recommended Citation
Pathak S, Stern C, Vambutas A. N-Acetylcysteine attenuates tumor necrosis factor alpha levels in autoimmune inner ear disease
patients. . 2015 Jan 01; 63(1-3):Article 616 [ p.]. Available from: https://academicworks.medicine.hofstra.edu/articles/616. Free full
text article.

This Article is brought to you for free and open access by Donald and Barbara Zucker School of Medicine Academic Works. It has been accepted for
inclusion in Journal Articles by an authorized administrator of Donald and Barbara Zucker School of Medicine Academic Works.

HHS Public Access
Author manuscript
Author Manuscript

Immunol Res. Author manuscript; available in PMC 2016 December 01.
Published in final edited form as:
Immunol Res. 2015 December ; 63(0): 236–245. doi:10.1007/s12026-015-8696-3.

N-acetylcysteine attenuates tumor necrosis factor-alpha levels
in autoimmune inner ear disease patients
Shresh Pathak1,3,5, Corey Stern1, and Andrea Vambutas1,2,3,4,5
1The

Feinstein Institute for Medical Research, Manhasset, New York

2The

Author Manuscript

Apelian Cochlear Implant Center, Department of Otolaryngology, North Shore-LIJ Health
System, New Hyde Park, New York

3Department

of Otolaryngology, Hofstra North Shore-LIJ School of Medicine at Hofstra University,
Hempstead, New York
4Department

of Molecular Medicine, Hofstra North Shore-LIJ School of Medicine at Hofstra
University, Hempstead, New York

5Department

of Otorhinolaryngology-Head & Neck Surgery, Montefiore Medical Center, Albert
Einstein College of Medicine, Bronx, New York

Abstract

Author Manuscript
Author Manuscript

Autoimmune Inner Ear Disease (AIED) is a poorly understood disease marked by bilateral,
rapidly progressive hearing loss triggered by unknown stimuli, which is corticosteroid responsive
in 60% of patients. Although the mechanism of the disease is not precisely understood, a complex
interaction of cytokines is believed to contribute towards the inflammatory disease process and
hearing loss. Previously we showed the role of TNF-α in steroid-sensitive, and IL-1β in steroidresistant immune mediated hearing loss. N-acetylcysteine (NAC), a broad spectrum antioxidant,
has been effective in other autoimmune disorders. Other studies have shown NAC to have a
protective adjunct role in human idiopathic sudden hearing loss, where the addition of NAC
resulted in better hearing recovery than with steroids alone, although the mechanism of this
protection was not elucidated. In the present study, we observed PBMCs from AIED patients
exhibited higher baseline TNF-α and MPO levels compared to normal healthy controls. NAC
effectively abrogates LPS-mediated TNF-α release from PBMC of both AIED patients and
controls. We demonstrated that in AIED patients, the TNF-α down-stream signaling pathway
appears aberrantly regulated, influencing both MPO and IL-8 expression. Given that NAC
effectively abrogated LPS mediated TNF-α release and exerted minimal effects on the
downstream targets of this pathway, we feel NAC may be a rational adjunct therapy for this
enigmatic disease, worthy of clinical exploration.
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1. Introduction
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Autoimmune inner ear disease (AIED) is an enigmatic disease of periodic episodes of
bilateral progressive hearing decline activated by unknown stimuli [1]. Recently, we have
identified a role of TNF-α in steroid-sensitive and IL-1β in steroid-resistant immune
mediated hearing loss [2, 3]. Furthermore, in a small cohort of patients, local administration
of the TNF-α inhibitor etanercept by intratympanic injection was able to maintain hearing
when systemic corticosteroid therapy was tapered [4], although use of systemic etanercept
met with less promising efficacy [5, 6].
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Reactive oxygen species (ROS) act as central mediators in the etiology of many autoimmune
diseases. Among numerous ROS-generating molecules, inducible nitric oxide synthase
(iNOS) and myloperoxidase (MPO) are hypothesized to play key roles. MPO is a prooxidant enzyme released from granules of activated leukocytes, neutrophils, monocytes, and
macrophages at inflammatory sites. When released as part of the innate host defense, it
generates free radicals and ROS [7, 8]. MPO plays a vital role in the autoimmune disease
process by escalating oxidative stress and oxidizing lipoproteins [9]. There are several
autoimmune diseases, such as Wegener’s granulomatosis [10], systemic lupus
erythematosus (SLE) [11], Goodpasture syndrome [12], Churg-Strauss syndrome [13], and
Cogan’s disease, a rare autoimmune vasculitis causing sensorineural hearing loss[14],
associated with the development of anti-neutrophil cytoplasm (ANCA) autoantibodies
against MPO. Furthermore, the perilymph of the inner ear is replete with apolipoproteins
and therefore a potential target of MPO [15].
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N-acetylcysteine (NAC), a broad spectrum antioxidant, is a precursor in the synthesis of
reduced glutathione (GSH) and acts as a free radical scavenger that protects cells from
oxidative damage [16]. NAC exerts anti-inflammatory effects [17]. NAC has been identified
to be otoprotective, and serve as a beneficial adjunctive therapy in hearing restoration. NAC
has been shown to have a protective adjunct role in idiopathic sudden hearing loss, where
the addition of NAC to corticosteroid therapy resulted in better hearing recovery than with
corticosteroids alone [18]. Furthermore, NAC ameliorated hearing loss in animal models of
noise-induced hearing loss in several studies [19–22]. NAC was found to be effective in
abrogating LPS-induced TNF alpha release in cardiomyocytes in dose dependent manner
[23] and in neuroblastoma cell lines [24].
Pulmonary studies have shown that NAC can reduce MPO levels in the serum/plasma of a
small cohort of healthy smokers the concentrations of MPO were reduced after NAC
treatment for 8 weeks [25]. The chronic use of NAC inhibited MPO activity in septic lung
injury rat model [26].
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Adjunct NAC therapy has also been effective in abating autoimmune disease in both animal
models of autoimmune disease and human autoimmune disease, although the mechanism of
action described has been varied. NAC in combination with aminoguanidine was found to
be effective in reducing oxidative stress in experimental autoimmune encephalomyelitis
(EAE) [27]. In animal models of autoimmune thyroiditis, adjunct treatment with NAC
reduced oxidative stress and the immune infiltration, thereby leading to a restoration of
thyroid morphology [28]. NAC therapy also reduced disease severity in a clinical trial of
systemic lupus erythematosus (SLE), although the mechanism was ascribed to blocking the
mammalian target of rapamycin in T cells [29]. Based on our prior observations that steroid
sensitive AIED patients exhibit higher pre-treatment levels of TNF-α [2], we hypothesized
that this elevated TNF-α induces expression of MPO which results in oxidative damage and
further hearing loss. We further hypothesized that treatment with NAC can partially
abrogate TNF-α mediated induction of MPO and subsequent oxidative damage making it a
good candidate to be used for adjunct therapy.
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Materials and Methods
Subjects
This study was approved and monitored by the Institutional Review Board (IRB) of the
North Shore Long Island Jewish Health system. Patients were identified by several
neurotologists. All individuals who were included in study gave signed informed consent.
Inclusion criteria were based on Niparko et al. study group guidelines [30]. A total of 64
AIED patients and 31 control subjects were recruited for these studies. The control cohort
consisted of subjects of similar age, gender and ethnic background, who denied a history of
hearing loss or autoimmune disease.
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Human PBMC culture and stimulation
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PBMCs from AIED patients and control subjects were collected in an identical fashion and
were separated by Ficoll density gradient as previously described [3]. Isolated PBMCs were
washed twice with 1 X RPMI (GIBCO) and incubated in RPMI 1640 supplemented with
10% (v/v) FBS (Atlanta Biologicals GA; a single lot of FBS was used for all experiments),
100 units/ml penicillin, 100 μg/ml streptomycin and 4.1 mM glutamine and plated at 1x106
cells/ml in 24-well plate (Costar). Preliminary experiments were done to identify the kinetics
of TNF-α release after stimulation with LPS, with maximal release plateauing between 4
and 24 hours (supplemental figure 1). PBMCs (1 x 106 per ml) isolated from control
subjects were subjected to treatment with and without 1 μg/ml LPS for different time points
(1h to 24 h). For rest of the experiments, PBMCs were treated with either 5 mM N-acetyl-Lcysteine (NAC), 1 μg/ml LPS E. coli (0111:B4) (both from Sigma), 10 ng/ml recombinant
TNF-α, recombinant myloperoxidase (1.5μg/ml) (both from R&D systems), alone or in
combination with NAC. The optimal concentrations of these reagents were previously
identified by culturing PBMC with increasing concentrations of these reagents to identify
the maximal concentration that could be used without affecting cell viability. All PBMC
samples were cultured overnight (16 h) at 37°C in 5% CO2 and compared with similarly
cultured, unstimulated PBMC. Cell viability was measured after 16 h by Trypan blue dye
exclusion method using the Cellometer Auto T4 automated cell counter (Nexcelom
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Biosciences). At the end of all incubations, samples were centrifuged and supernatants were
collected and stored at −20 °C.
Monocyte and Neutrophil isolation
Monocytes and Neutrophils were isolated from same patient from same lot of blood by
MACS monocyte isolation kit II™ and MACSxpress™ Neutrophil Isolation Kit both from
(Miltenyi Biotec, Auburn,CA). The purity of negatively selected monocytes and neutrophils
was determined by flow cytometry (FACSCanto II; BD Biosciences) using anti-CD14PE
Abs (BD Immunocytometry Systems, San Jose, CA) and anti-CD 15 FITC along with
Pacific Blue™ Mouse Anti-Human CD16 Clone 3G8(both from BD Biosciences)
respectively. Purity for these experiments exceeded 80% and 90% respectively.
ELISA Methodology
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TNF-α and IL-8 ELISA—Supernatant TNF-α (GE Healthcare) and IL-8 (R&D Systems)
levels were quantified using a sandwich ELISA as per the manufacturer’s instructions. An 8point standard curve was constructed for each assay using a quadratic fit, and data were
interpolated using BioLinx 2.2 software (Synatech Laboratories Inc). Each sample was run
in duplicate. Greater than 70% of all samples were run on replicate plates: the variance
between replicate sets was 0.08 and 0.001 for TNF-α and IL-8.
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MPO ELISA—Plasma and supernatant MPO levels were quantified using Human MPO
Instant ELISA (eBioscience) as per the manufacturer’s instructions. The sensitivity of the
assay was 0.026 ng/ml. An 8-point standard curve was constructed for each assay using a
quadratic fit, and data were interpolated using BioLinx 2.2 software (Synatech Laboratories
Inc). Each sample was run in duplicate. A least 19 samples from AIED patients and 4
control subjects were replicated on different dates. The variance between replicate sets was
0.03.
Thyroid peroxidase (TPO) ELISA—Plasma TPO levels were measured according to the
manufacturer’s instructions (Abnova). Concentrations were calculated using a 4-parameter
logistic curve. All samples were run in duplicate. The variance between replicate sets was
0.005.
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IgG ELISAs for antibodies to MPO and TPO—Plasma anti-MPO IgG and anti-TPO
IgG levels were measured by ELISA according to the manufacturer’s instructions (Abnova).
Anti-MPO IgG concentrations were calculated using a 4-parameter logistic curve. For the
plasma anti-TPO IgG concentration, a standard curve was constructed using a quadratic fit.
All samples were run in duplicate. The variance between replicate sets was 0.001, and 0.01
respectively.
Western blotting
Isolated proteins from monocytes, neutrophils and PBMCs were separated on 12 % MiniPROTEAN® TGX™ Precast Gel (BIO-RAD) and then transferred electrophoretically to
PVDF membrane (BIO-RAD). The blot was then blocked with 5% Nonfat dry milk
(NFDM) in Tris-buffered saline (TBS) with Tween 20 (0.5%, v/v) for 1 h at room

Immunol Res. Author manuscript; available in PMC 2016 December 01.

Pathak et al.

Page 5

Author Manuscript

temperature and subsequently incubated overnight at 4 degree with Anti MPO at dilution of
1:750 (DAKO) in TBS-Tween 20 (0.5%, v/v) [TBST] with 5% (w/v) NFDM. Following 3
washes of 5 min each with TBST, the blots were incubated with HRP-conjugated goat antirabbit IgG (R &D systems) (1:5000) in blocking buffer for 45 minutes at room temperature.
After three washes with TBST, the blot was developed with Clarity ECL Western Blot
Substrate kit (BIO-RAD) and exposed to Kodak Scientific Imaging X-OMAT LS Film from
Carestream Health (Rochester, NY). Anti-actin antibody (Sigma) was used as loading
control.
Statistical analysis
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The data are expressed as mean ± standard error of the mean (SEM) and analyzed using
GraphPad Prism 5 (GraphPad Software, San Diego, CA). The differences between groups
were evaluated using the Mann–Whitney U test or by one-way analysis of variance
(ANOVA). Post hoc testing was performed using a Bonferroni’s comparison on selected
columns. P values less than or equal to 0.05 were considered significant.

Results
NAC effectively abrogates LPS-mediated TNF-α release from PBMC of both AIED patients
and controls
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PBMCs isolated from AIED (N=12) patients and healthy control subjects (N=5) were either
treated with 1 μg/ml LPS, 5 mM NAC, co-cultured with the combination of 1 μg/ml LPS
plus 5 mM NAC, or left untreated for 16 hours. NAC, in combination with LPS, reduced
TNF-α release when compared with LPS alone in AIED patients and control subjects: in
LPS stimulated PMBC from AIED subjects, NAC reduced TNF-α release from 653 pg/ml to
280 pg/ml (a 57% reduction), and in PBMC from control subjects, NAC reduced TNF-α
release from 445 to 173 pg/ml (a 61% reduction) (Fig. 1, p=0.03, Mann–Whitney U test).
NAC had a marginal effect on unstimulated PBMC, largely because minimal expression of
TNF-α secretion was detected (in PMBC from AIED subjects, NAC reduced TNF-α release
from 21 to 12 pg/ml, and in PBMC from control subjects, NAC reduced TNF-α release from
13 to 8 pg/ml). Based on our prior observations of elevated TNF-α secreted protein levels in
a subset of AIED patients, we queried whether myeloperoxidase (MPO) was elevated in
these AIED patients as well.
AIED patients have elevated plasma levels of MPO
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Plasma samples from 50 AIED patients and from 24 normal healthy control subjects were
tested by sandwich ELISA to compare their MPO plasma levels. MPO levels were
significantly increased in the plasma of AIED patients compared with controls (231 ng/ml of
AIED patients plasma versus 47.76 ng/ml of plasma from control subjects (p<0.0001 by the
Mann–Whitney U test)) (Fig. 2). The data suggests that increase in MPO levels is associated
with AIED disease.
MPO can be marginally induced by TNF-α, and blocked by NAC
To determine whether MPO induction was TNF-α mediated, PBMCs isolated from AIED
(N=8) patients and healthy control subjects (N=6) were either treated with 10 ng/ml TNF-α
Immunol Res. Author manuscript; available in PMC 2016 December 01.

Pathak et al.

Page 6

Author Manuscript

or 5 mM NAC, co-cultured with 10 ng/ml TNF-α plus 5 mM NAC, or left untreated for 16
h. NAC had a marginal effect on unstimulated PBMC. NAC reduced MPO in unstimulated
PMBC from AIED patients and control subjects by 20% and 21%, respectively (Fig. 3a).
Similarly, basal MPO release from untreated PBMC of AIED patients (N=12) was 3.3 times
greater as compared with release from PBMC of control subjects. NAC reduced the TNF-αmediated marginal increase in MPO release in AIED patients p<0.05 (one way ANOVA
followed by post hoc analysis using a Bonferroni’s comparison on selected columns) (Fig.
3a). LPS stimulated PBMC cultures from AIED patients were largely refractory to NAC
treatment, as NAC treatment resulted in only a minimal decrease in MPO levels from LPS
stimulated PBMC (Fig. 3a). We suspect this failure of NAC to mitigate the LPS effect may
be a result of LPS induction of other pro-inflammatory cytokines other than TNF-α, and that
the NAC effect may be limited to TNF-α (Fig. 3a).
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Neutrophils and monocytes produce MPO
To see if increased MPO levels could be ascribed to a specific cell type, we isolated
monocytes and neutrophils from an AIED patient and by western blot compared their
intracellular MPO contents with total PBMC isolated from same patient from same lot of
blood. Western blotting indicated that MPO is expressed by both neutrophils and monocytes
(Fig. 3b). However, the majority of MPO is produced by the neutrophil fraction (Fig. 3b).
TNF-α induces IL-8 release, which is marginally reduced with NAC co-culture

Author Manuscript

PBMCs isolated from AIED patients (N=4) and healthy control subjects (N=3) were either
treated with 10 ng/ml recombinant TNF-α, LPS, 5 mM NAC, co-cultured with 10 ng/ml
recombinant TNF-α plus 5 mM NAC or 1 μg/ml LPS or co-cultured with 1 μg/ml LPS plus
5 mM NAC and compared to untreated PBMC. NAC’s effect on unstimulated PBMC in
AIED subjects and control subjects could not be judged as practically there was no basal
secretion in both cases. Both TNF-α, and LPS were able to induce IL-8 release from PBMCs
of AIED patients, although, again, the LPS effect was substantially greater. The addition of
NAC to either TNF-α or LPS stimulated cultures failed to substantially reduce IL-8 levels
suggesting NAC exerts a greater effect on TNF-α expression rather than IL-8 (Fig. 4).
TNF-α mediated MPO and IL-8 induction is unidirectional
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Given that TNF-α is capable of inducing MPO, we queried whether MPO could reciprocally
induce TNF-α. PBMCs isolated from AIED patients (N=4) and healthy control subjects
(N=5) were either treated with 1.5 μg/ml recombinant MPO, 5 mM NAC, co-cultured with
1.5 μg/ml MPO plus 5 mM NAC or left untreated for 16 h. MPO treatment does not induce
TNF-α (Fig. 5a). Interestingly, co-culture with MPO negated the ability of NAC to inhibit
TNF-α release in AIED PBMC, suggesting polarization of AIED PBMC to a refractory
phenotype. Similarly, we also investigated whether IL-8 can induce TNF-α. PBMCs isolated
from healthy control subjects (N=5) were either treated with 10 ng/ml recombinant IL-8, 5
mM NAC, co-cultured with 10 ng/ml IL-8 plus 5 mM NAC, or left untreated for 16 h. IL-8
was similarly unable to induce TNF-α release from PBMCs of control subjects (Fig. 5b). A
similar pattern was observed in a small cohort of AIED patients (data not shown). These
observations led us to conclude that TNF-α induction of MPO and IL-8 is unidirectional,
and a feedback loop does not appear to be present.
Immunol Res. Author manuscript; available in PMC 2016 December 01.
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Anti-MPO IgG antibodies were not detected in AIED patients
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Antibodies to MPO have been detected in many autoimmune diseases. Since plasma MPO
levels are elevated in our patient cohort, we hypothesized that our patients may have antiMPO antibodies. Plasma from 29 AIED patients and 10 normal healthy control subjects was
tested by ELISA to determine if AIED patients exhibited elevated anti-MPO plasma IgG
levels compared with controls. No significant anti-MPO IgG antibodies were detected in
either AIED patients or control subjects (Fig. 6). These results suggest that although MPO is
elevated, it is not the target of an aberrant antibody-mediated immune response.
AIED patients have mildly elevated TPO levels and autoantibodies to TPO
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Since MPO shares great extent of homology with thyroperoxidase (TPO) and anti-TPO
antibodies are readily detected in patients with various autoimmune diseases, we measured
TPO protein levels in plasma of AIED patients (N= 30) and normal healthy controls (N=10)
by a sandwich ELISA. TPO plasma levels were slightly greater in AIED patients and
controls (49.02 pg/ml of serum for AIED patients versus 40.37 pg/ml of serum for control
subjects), although this difference is marginal and would require a substantially larger cohort
to draw any conclusions (Fig. 7a). Similar to the rationale for investigating the presence of
anti-MPO antibodies, we also questioned whether our AIED cohort had anti-TPO
antibodies. Plasma IgG levels of anti-TPO auto-antibodies in the same 26 AIED patients
were 17 fold higher than in the 10 normal controls (Fig. 7b). Anti-TPO antibodies are
prevalent in older adults[31], to rule out that possibility we segregated our TPO IgG ELISA
data (Fig. 7c) on the basis of a threshold of 10 U/ml. We observed that the group with TPO
IgG < 10 U/ml (mean= 0.67) had an age mean of 54 years old vs. the group of >10 U/ml
(mean value= 277.94) with an age mean of 41 years of age. This discounts the possibility
that increased TPO IgG levels in AIED patients are due to more aged AIED population.

Discussion
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Previously we observed that PBMCs from AIED patients exhibited greater TNF-α release
compared to normal healthy controls [2]. Here we show that PBMC treatment with NAC
abrogates approximately 60% of LPS-mediated TNF-α release from PBMCs of both AIED
patients and controls. Other studies have also noticed similar inhibition with NAC when
induced by LPS [23]. We noticed that this effect is dose dependent (data not shown), with
the 5 mM NAC concentration being optimal. Given that TNF-α is able to influence MPO
[32] and IL-8 [33] expression in other systems, we investigated and ascertained that in AIED
patients, the TNF-α down-stream signaling pathway appears aberrantly regulated (Fig 8).
This TNF-α mediated IL-8 and MPO induction appears to be unidirectional because MPO
and IL-8 treatment does not induce TNF-α, but interestingly, the addition of MPO may
cause refractoriness in NAC-mediated TNF-α inhibition in AIED patients (Fig 5).
Clinically, NAC treatment has been observed to enhance the effect of corticosteroids in
hearing recovery [18]. We have previously demonstrated that, specifically, corticosteroid
sensitive AIED correlated with high TNF-α levels [2]. NAC has been effective in inhibiting
TNF-α [23] and IL-8 [34, 35] in other studies. Notably, TNF-α appears to be a potential
target of NAC, as NAC does not exert a strong effect on the further downstream targets
MPO and IL-8. Furthermore, NAC was ineffective in reducing IL-1β levels (data not

Immunol Res. Author manuscript; available in PMC 2016 December 01.

Pathak et al.

Page 8

Author Manuscript
Author Manuscript
Author Manuscript
Author Manuscript

shown). Others have shown that NAC’s effect may be via suppression of TNF mediated
NFkB activation [36], [37], [38] Whether this effect is specific to a particular cell type is
unknown, however, neutrophils have been observed to have increased NFkB activation and
IL-8 expression [39], although PPARs act to inhibit inflammation through NFkB occurs in
monocytes, B and T cells [40] suggesting it may not be limited to one cellular subset.
Plasma levels of MPO in AIED patients were almost 5 fold higher when compared with
normal healthy subjects (Fig 2), indicating that high MPO levels in AIED could be a result
of increased TNF-α expression, although elevation of MPO is likely the result of a number
of factors. Future experiments will determine the precise effect of anti-TNF neutralizing
antibodies on MPO expression in these patients, although TNF inhibition has not been
clinically effective in AIED patients [5], [6], despite possible benefit in patients with
Cogan’s disease [14]. As anticipated, MPO expression is predominantly observed in the
neutrophil fraction and to a lesser degree in the monocytes fraction which is consistent with
prior observations [41] Future studies will characterize the cell frequency in AIED patients,
as neither we, or other investigators have determined if any irregularities exist. Others have
shown that MPO is important in LDL oxidation and resultant monocyte differentiation into
classical or alteratively activated macrophages based on the amount of oxidized LDL [42],
suggesting that MPO activity may dictate monocyte differentiation and disease progression
or remission in other systems based on the local microenvironment. It is certainly possible
that prolonged treatment with NAC may improve MPO repression. Given that we detected
elevated MPO in our patient cohort, and MPO autoantibodies have been widely observed in
different autoimmune diseases, we decided to investigate MPO antibody levels in our patient
cohort. We were unable to detect MPO autoantibodies in these patients as measured by
plasma anti-MPO IgG ELISA (Fig. 6), which highlights the difference between this patient
cohort and Cogan’s patients as they have anti-MPO antibodies [14]. MPO and TPO share up
to 42 % sequence homology [43–45]. The relationship between TPO and MPO is also
manifested by potentially shared epitopes in autoimmune thyroid disease patients between
these two antigens [46]. Although TPO levels in the plasma were marginally higher in AIED
patients compared with controls, AIED patients had significantly higher anti-TPO IgG levels
when compared with normal healthy controls (Fig. 7). Although anti-TPO antibodies are
prevalent in older adults[31], when we segregated our TPO IgG ELISA data on the basis
age, we observed that the younger patients had substantially higher anti-TPO titers. The
group with low anti-TPO IgG < 10 U/ml (mean= 0.67 U/ml) had a mean age of 54 years old
versus the group of >10 U/ml (mean = 277.94 U/ml) with a mean age of 41 years old. These
results suggest that the high anti-TPO IgG values are not due to a more aged AIED
population, but rather may be associated with development of an autoimmune disease (Fig.
8), as many AIED patients have a wide variety of autoantibodies detected in their sera [47].
It is unlikely, however, that these autoantibodies have a pathogenic role in the disease
process. Presence of these and other auto-antibodies in AIED is variable, and neither assists
in clarifying the diagnosis of AIED, nor do they dictate treatment[47].
Our studies demonstrated that TNF-α is capable of inducing IL-8 release (Fig. 4). IL-8
instilled into the round window membrane of the inner ear of rats resulted in an
inflammatory infiltrate, however, interestingly, at the time of resultant sensorineural hearing
loss, the neutrophil infiltrate had resolved, leaving only resident macrophages, suggesting
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their potential role in the development of immune mediated hearing loss [48]. IL-8
expression is enhanced in Th17 polarizing conditions, consistent with development of an
autoimmune phenotype [49], especially in the background of TNF-α expression [50].
Interestingly, reduced IL-8 levels have been observed in patients with thyroid disease [51].
Given that AIED patients that appear to have anti-TPO antibodies, and elevated IL8 in
response to TNF, future studies will further investigate the role of IL-8 in these patients.
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Taken together, our data demonstrates the ability of NAC to inhibit TNF-α expression in
these AIED patients, and may elucidate why adjuvant therapy with NAC has shown to be
clinically beneficial in hearing recovery. Given that we have observed that TNF-α
influences the expression of MPO and IL-8 in these patients and may potentiate autoimmune
disease, the equilibrium between the release of oxidants, and their inactivation by
antioxidants could therefore be decisive in clinical disease progression or remission. The
above data emphasize that use of antioxidants like NAC may be an important adjunct
therapy for the treatment of this poorly understood disease, and further understanding of the
molecular mechanism of action may elucidate further biologic targets for intervention.
In conclusion, we demonstrate the ability of NAC to inhibit TNF-α expression in AIED
patients, which may explain the clinical benefit of adjuvant NAC antioxidant therapy
hearing recovery.

Supplementary Material
Refer to Web version on PubMed Central for supplementary material.
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AIED

Autoimmune Inner Ear Disease

NAC

N-acetyl-L-cysteine

GSH

L-γ-glutamyl-L-cysteinyl-glycine

ROS

reactive oxygen species

MPO

Myeloperoxidase

TPO

Thyroperoxidase

EAE

experimental autoimmune encephalomyelitis
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Fig. 1. NAC abrogates LPS-mediated TNF-α release from PBMC of both AIED patients and
controls

PBMCs isolated from AIED patients (N=12) and healthy control subjects (N=5) were
treated with 1 μg/ml LPS, 5 mM NAC, 5 mM NAC + 1 μg/ml LPS or left untreated for 16 h.
LPS-mediated TNF-α release was significantly reduced by NAC in AIED patients (p = 0.03,
Mann–Whitney U test) compared to LPS alone. In case of control subjects, there was trend
towards reduction of TNF release, however significance was not achieved (p=0.09). Error
bars show ± SEM.
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Fig. 2. AIED patients have higher plasma levels of MPO compared to control subjects

Plasma samples from AIED patients (N=50) and normal healthy (N=24) control subjects
were tested by sandwich ELISA to compare their MPO levels. MPO plasma levels were
significantly increased in AIED patients (p<0.0001) compared with controls by the Mann–
Whitney U test with 95% CI. Error bars show ± SEM
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Fig. 3. MPO is generated by both neutrophils and monocytes fractions of PBMC and NAC
reduces TNF-α-mediated MPO release from PBMC of both AIED patients and controls
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a. A sandwich ELISA was done on stimulated PBMCs isolated from AIED patients and
healthy control subjects. PBMC from AIED patients were either treated with 10 ng/ml TNFα (8 AIED patients) or 1 μg/ml LPS (16 AIED patients) +/− 5 mM NAC, and compared to
untreated PBMC, or PBMC from control subjects (N=6) cultured under the same conditions
for 16 h. NAC in combination with TNF-α was able to reduce MPO release when compared
with TNF-α alone in PBMC from AIED patients and control subjects. Comparisons were
made by one-way analysis of variance (ANOVA) p < 0.0001, followed by post hoc testing
using a Bonferroni’s comparison test on selected columns. TNF-α induced MPO release
compared with TNF-α + NAC achieved statistical significance p < 0.05 in AIED patients. b.
Neutrophils (Neut), monocytes (Mono) and total PBMCs were isolated from an AIED
patient and treated with LPS 1 μg/ml or (N=4) and healthy control subjects (N=3) were
either treated with 10 ng/ml recombinant TNF-α or 5 mM NAC, co-cultured with 10 ng/ml
recombinant TNF-α + 5 mM NAC, 1 μg/ml LPS, co-cultured with 1 μg/ml LPS + 5 mM
NAC, or left untreated for 16 h. TNF-α and LPS were able to induce IL-8 release from
PBMCs of AIED patients. Addition of NAC to either TNF-α or LPS cultures resulted in
only a minimal reduction of IL-8 release.
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Fig. 4.
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Fig. 5. IL-8 or MPO do not augment TNF-α release
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a. PBMCs isolated from AIED patients (N=4) and healthy control subjects (N=5) were
either treated with 1.5 μg/ml recombinant MPO, 5 mM NAC, co-cultured with 1.5 μg/ml
MPO + 5 mM NAC or left untreated for 16 h. MPO treatment does not induce TNF-α. b.
PBMCs isolated from healthy control subjects (N=5) were either treated with 10 ng/ml
recombinant IL-8, 5 mM NAC, co-cultured with 10 ng/ml IL-8 + 5 mM NAC or left
untreated for 16 h. IL-8 was unable to induce TNF-α release from PBMCs of control
subjects.
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Fig. 6. MPO IgG plasma levels were absent in AIED patients and control subjects

Plasma samples from 29 AIED patients and 10 normal healthy control subjects were tested
by ELISA were compared with a positive control (MPO antibodies in serum/buffer) and a
negative control (PBS, BSA detergent sodium azide 0.09%) to identify whether AIED
patients made anti-MPO IgG antibodies. Anti-MPO IgG plasma levels were in the same
range as of negative control for both AIED patients as well as control subjects. Error bars
show ± SEM.
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Fig. 7. AIED patients have marginally elevated TPO levels; however exhibit enhanced anti-TPO
antibodies compared with age matched controls
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a. Plasma samples from 30 AIED patients and 10 normal healthy control subjects were
tested by sandwich ELISA to compare their TPO levels. TPO plasma levels were almost
same in AIED patients compared with controls (49.02 pg/ml for AIED patients versus 40.37
pg/ml for control subjects). Error bars show ± SEM. b. Plasma samples from AIED patients
(N=26) and normal healthy (N=10) control subjects were tested by ELISA to compare their
TPO IgG levels. TPO IgG plasma levels were very high (17 fold) in AIED patients’ plasma
when compared with control subjects. Error bars show ± SEM. c. Analysis of TPO IgG
threshold relative to patient age. We segregated our AIED patient (N=26) TPO IgG
ELISA data into two groups on the basis of a threshold of 10 U/ml of TPO IgG. The lower
threshold group of <10U/ml (N=19 patients) had a mean value of TPO IgG of 0.67 with a
mean age of 54 years old vs. the higher threshold group of >10U/ml (N=7 patients) with a
mean value of TPO IgG of 277.94 with a mean age of 41 years old.
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Fig. 8.

Schematic diagram illustrating the proposed signaling pathway.
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